{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:38:08Z","timestamp":1761896288421},"reference-count":39,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.3892\/mco.2016.857","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T04:55:26Z","timestamp":1460609726000},"page":"165-170","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy"],"prefix":"10.3892","volume":"5","author":[{"given":"SHIH-HAO","family":"YOUNG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TIEN-HSIN","family":"WEI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHUNG-CHI","family":"LIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHI-JEN","family":"CHU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FA-YAUH","family":"LEE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAY-ING","family":"YU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"REI-HWA","family":"LU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHIAO-YU","family":"CHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PEI-LING","family":"YANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MEI-HUI","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HAN-CHIEH","family":"LIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"key":"key20180107150439_b1-mco-0-0-857","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"key20180107150439_b2-mco-0-0-857","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"key":"key20180107150439_b3-mco-0-0-857","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"key":"key20180107150439_b4-mco-0-0-857","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann Intern Med"},{"issue":"Suppl 5","key":"key20180107150439_b5-mco-0-0-857","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"key20180107150439_b6-mco-0-0-857","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20180107150439_b7-mco-0-0-857","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study","volume":"70","author":"Yeo","year":"2003","journal-title":"J Med Virol"},{"key":"key20180107150439_b8-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br J Cancer"},{"key":"key20180107150439_b9-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","article-title":"Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma","volume":"37","author":"Cheng","year":"2003","journal-title":"Hepatology"},{"key":"key20180107150439_b10-mco-0-0-857","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107150439_b11-mco-0-0-857","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V99.7.2324","article-title":"High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation","volume":"99","author":"Lau","year":"2002","journal-title":"Blood"},{"key":"key20180107150439_b12-mco-0-0-857","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s10157-011-0464-7","article-title":"Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy","volume":"15","author":"Ohishi","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"key20180107150439_b13-mco-0-0-857","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy","volume":"131","author":"Hui","year":"2006","journal-title":"Gastroenterology"},{"key":"key20180107150439_b14-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1478-3231.2009.02071.x","article-title":"Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: Is the serum hepatitis B virus profile reliable?","volume":"29","author":"Ferraro","year":"2009","journal-title":"Liver Int"},{"key":"key20180107150439_b15-mco-0-0-857","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/jhep.2002.35068","article-title":"Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation","volume":"36","author":"Lau","year":"2002","journal-title":"Hepatology"},{"key":"key20180107150439_b16-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"key20180107150439_b17-mco-0-0-857","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.03099.x","article-title":"Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy","volume":"115","author":"Rossi","year":"2001","journal-title":"Br J Haematol"},{"key":"key20180107150439_b18-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/jhep.2002.36156","article-title":"Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients","volume":"36","author":"Chan","year":"2002","journal-title":"Hepatology"},{"key":"key20180107150439_b19-mco-0-0-857","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","article-title":"A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial","volume":"47","author":"Hsu","year":"2008","journal-title":"Hepatology"},{"key":"key20180107150439_b20-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.23190","article-title":"AASLD practice guidelines chronic hepatitis B: Update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"key20180107150439_b21-mco-0-0-857","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jcv.2011.01.019","article-title":"An improved Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg)","volume":"51","author":"Lou","year":"2011","journal-title":"J Clin Virol"},{"key":"key20180107150439_b22-mco-0-0-857","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/JCM.01306-10","article-title":"Performance of version 2.0 of the Cobas AmpliPrep\/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification","volume":"48","author":"Chevaliez","year":"2010","journal-title":"J Clin Microbiol"},{"key":"key20180107150439_b23-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1073\/pnas.83.6.1627","article-title":"Hepatitis B virus DNA contains a glucocorticoid-responsive element","volume":"83","author":"Tur-Kaspa","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107150439_b24-mco-0-0-857","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/bjc.2011.4","article-title":"Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy","volume":"104","author":"Yun","year":"2011","journal-title":"Br J Cancer"},{"key":"key20180107150439_b25-mco-0-0-857","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1440-1746.2012.07280.x","article-title":"Hepatitis B virus reactivation associated with anti-neoplastic therapy","volume":"28","author":"Yeo","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"key20180107150439_b26-mco-0-0-857","first-page":"3035","article-title":"Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy","volume":"24","author":"Hsu","year":"2004","journal-title":"Anticancer Res"},{"key":"key20180107150439_b27-mco-0-0-857","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC): Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"key20180107150439_b28-mco-0-0-857","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"European Association For The Study Of The Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"key20180107150439_b29-mco-0-0-857","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"key20180107150439_b30-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","article-title":"Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"69","author":"Vassilopoulos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20180107150439_b31-mco-0-0-857","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"key20180107150439_b32-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"key20180107150439_b33-mco-0-0-857","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1365-2893.2010.01386.x","article-title":"Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy","volume":"18","author":"Li","year":"2011","journal-title":"J Viral Hepat"},{"key":"key20180107150439_b34-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/gut.2005.070763","article-title":"Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy","volume":"54","author":"Hui","year":"2005","journal-title":"Gut"},{"key":"key20180107150439_b35-mco-0-0-857","first-page":"1566","article-title":"Hepatitis and leukemia: Their relation to Australia antigen","volume":"44","author":"Blumberg","year":"1968","journal-title":"Bull N Y Acad Med"},{"key":"key20180107150439_b36-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jhep.2011.06.006","article-title":"Hepatitis B surface antigen quantification: Why and how to use it in 2011 - a core group report","volume":"55","author":"Chan","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"key20180107150439_b37-mco-0-0-857","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s12072-009-9149-7","article-title":"The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B","volume":"3","author":"Nguyen","year":"2009","journal-title":"Hepatol Int"},{"key":"key20180107150439_b38-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00042737-200411000-00021","article-title":"Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers","volume":"16","author":"Chen","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20180107150439_b39-mco-0-0-857","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","article-title":"Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response","volume":"5","author":"Chan","year":"2007","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mco.2016.857\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T10:04:50Z","timestamp":1515319490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mco.2016.857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,14]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,4,14]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.3892\/mco.2016.857"],"URL":"https:\/\/doi.org\/10.3892\/mco.2016.857","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,14]]}}}